Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038402 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 74
- Enrollment target
NCT00038402: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00038402 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 74 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038402, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 74 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy treatment of patients newly diagnosed with operable breast cancer. Other objectives: 1) to evaluate the potential of this therapy to reduce the size of the tumor and increase the possibility of breast conservative surgery, 2) evaluate the ability of this regimen to prevent recurrence of breast cancer and impact on survival, 3) determine side effect profile with the addition of Herceptin, and 4) evaluate significance of HER2 expression by two different methods.
Interventions
- DRUG Fluorouracil
- DRUG Cytoxan
- DRUG Taxol
- DRUG Epirubicin
- DRUG Herceptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2001-04 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038402
The ClinicalTrials.gov registry entry for NCT00038402 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fluorouracil is the first listed.
NCT00038402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038402 about?
NCT00038402 is a clinical study titled "Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer". The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy treatment of patients newly diagnosed with operable breast cancer. Other objectives: 1) to evaluate the potential of this therapy to reduce the size of the tumor and increase the possibility of breast conser...
What is the current status of trial NCT00038402?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 74 participants. The study started on 2001-04. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00038402?
The interventions under investigation include: Fluorouracil (DRUG), Cytoxan (DRUG), Taxol (DRUG), Epirubicin (DRUG), Herceptin (DRUG).
Who is sponsoring clinical trial NCT00038402?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.